07 October 2020: Clinical Research
Overexpression of Facilitates Tumor Development and Is Correlated with Poor Prognosis in Clear Cell Renal Cell Carcinoma
Peng Chen 1BCDEF* , Ziying Zhang 12BCDEF* , Xiang Chen 1ACDEG*DOI: 10.12659/MSM.926755
Med Sci Monit 2020; 26:e926755
Table 2 Univariate and multivariate analyses of OS in patients with ccRCC in the TCGA database.
| Variable | Mean survival (Mo) | 95% CI | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |||
| Total | 44.9 | 42.0–47.9 | ||||
| Age (years) | ||||||
| ≤60 | 46.9 | 42.6–51.2 | Ref | |||
| >60 | 43 | 39–47.1 | 1.61 (1.17–2.21) | 0.004 | 1.25 (0.9–1.75) | 0.188 |
| Sex | ||||||
| Female | 45 | 39.6–50.3 | Ref | |||
| Male | 44.9 | 41.4–48.5 | 0.96 (0.69–1.34) | 0.811 | ||
| Race | ||||||
| Asian | 30.6 | 17.1–44.2 | Ref | |||
| Black | 26.2 | 19.2–33.1 | 2.01 (0.26–15.7) | 0.507 | ||
| White | 47.3 | 44.1–50.4 | 1.89 (0.26–13.52) | 0.527 | ||
| T classification | ||||||
| T1+T2 | 47.6 | 44–51.3 | Ref | |||
| T3+T4 | 41 | 36–46.1 | 2.88 (2.09–3.97) | 0.64 (0.34–1.2) | 0.164 | |
| N classification | ||||||
| N0 | 45.2 | 40.8–49.5 | Ref | |||
| N1 | 27.2 | 11.7–42.6 | 2.81 (1.36–5.83) | 0.005 | ||
| M classification | ||||||
| M0 | 47.1 | 43.9–50.3 | Ref | |||
| M1 | 35.2 | 27.4–43.1 | 4.57 (3.3–6.32) | 1.31 (0.84–2.05) | 0.236 | |
| TNM stage | ||||||
| I+II | 48 | 44.4–51.7 | Ref | |||
| III+IV | 40.2 | 35.3–45 | 3.61 (2.59–5.03) | 2.54 (1.19–5.41) | 0.016 | |
| Histologic grade | ||||||
| G1+G2 | 46.6 | 42.4–50.9 | Ref | |||
| G3+G4 | 43.5 | 39.4–47.6 | 2.63 (1.83–3.76) | 1.57 (1.06–2.32) | 0.024 | |
| Tumor status | ||||||
| Tumor-free | 46.5 | 43.1–50 | Ref | |||
| With tumor | 40.9 | 35.3–46.4 | 5.41 (3.89–7.53) | 4.75 (2.32–9.75) | ||
| Laterality | ||||||
| Left | 43.5 | 39.4–47.7 | Ref | |||
| Right | 46.2 | 42–50.3 | 0.66 (0.48–0.91) | 0.010 | 0.73 (0.53–1.01) | 0.057 |
| Relapse | ||||||
| No | 45.3 | 41.8–48.8 | Ref | |||
| Yes | 44.2 | 38.7–49.8 | 4.17 (3.0–5.8) | 0.64 (0.31–1.32) | 0.225 | |
| Neoadjuvant treatment history | ||||||
| No | 45.1 | 42.1–48.1 | Ref | |||
| Yes | 39.7 | 24–55.3 | 2.19 (1.15–4.16) | 0.017 | 1.22 (0.62–2.39) | 0.561 |
| PKMYT1 expression | ||||||
| Low | 47.7 | 43.7–51.7 | Ref | |||
| High | 42.1 | 37.8–46.4 | 1.82 (1.32–2.52) | 1.79 (1.29–2.49) | 0.001 | |
| OS – overall survival; ccRCC – clear cell renal cell carcinoma; TCGA – The Cancer Genome Atlas; HR – hazard ratio; 95% CI – 95% confidence interval. | ||||||